Fig. 4From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPDMorning trough FEV1 (full analysis set). Data are least squares means treatment–placebo differences and 95% confidence intervals. *p < 0.05; †p < 0.01 vs placebo. Least squares mean changes from baseline in the placebo group (N = 79) were −56, −32, −49 and −28 mL at Weeks 1, 2, 3 and 4, respectivelyBack to article page